MARKET

SYBX

SYBX

Synlogic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.580
+0.020
+0.78%
After Hours: 2.580 0 0.00% 16:24 09/20 EDT
OPEN
2.580
PREV CLOSE
2.560
HIGH
2.638
LOW
2.520
VOLUME
119.58K
TURNOVER
--
52 WEEK HIGH
14.59
52 WEEK LOW
2.310
MARKET CAP
81.84M
P/E (TTM)
-1.3847
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SYBX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SYBX News

  • Those Who Purchased Synlogic (NASDAQ:SYBX) Shares A Year Ago Have A 78% Loss To Show For It
  • Simply Wall St..09/12 17:56
  • Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure
  • Business Wire.09/06 20:46
  • The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug
  • Benzinga.09/05 12:12
  • The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug
  • Benzinga.09/05 12:12

More

Industry

Pharmaceuticals
+1.04%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Name
Price
%Change

About SYBX

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
More

Webull offers Synlogic Inc (SYBX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.